A Deeper Look Into our Development Pipeline
Viska’s technology utilizes a fusion protein with targeted delivery to EGFR-expressing cancer cells. Our primary indication is Glioblastoma with a direct path to IND-enabling studies in late 2025.
Program
Glioblastoma
Discovery
Development
Pre-Clinical
Clinical
Colorectal
Other EGFR Expressing Cancers
Partner with Us
Our fusion protein platform can be utilized in other diseases of interest by exchanging our antibody target. Collaborations with Industry Partners would allow us to expand our applications to help other hard-to-treat diseases.
If you are interested in working with us to expand this platform, please contact us!